Department of Pharmacy, The Second Hospital of Shandong University, Jinan, Shandong, China.
Department of Pediatrics, The Second Hospital of Shandong University, Jinan, Shandong, China.
Biomed Res Int. 2020 Feb 19;2020:2308124. doi: 10.1155/2020/2308124. eCollection 2020.
It has been recognized that people with obesity are more likely to have low growth hormone secretion. Recent studies have also confirmed that the abnormalities of the growth hormone/insulin-like growth factor 1 axis were associated with cardiovascular complications in people with obesity. However, little is known about whether recombinant human growth hormone therapy could improve cardiovascular and metabolic risks in obese children. This study aims to evaluate the effect of one-year growth hormone therapy on obesity-related comorbidities and to assess the safety in Chinese boys with obesity. Eighteen boys with obesity were treated with recombinant human growth hormone for one year. Anthropometric measurements, endocrine testing, and cardiovascular risk markers were performed in all obese boys in baseline, and follow-up visits were performed at 3 months, 6 months, 9 months, and one year, respectively. After one year of recombinant human growth hormone treatment, the body mass index standard deviation scores decreased ( < 0.001) and insulin-like growth factor 1 levels increased ( < 0.001). GH treatment also reduced low density lipoprotein cholesterol ( < 0.001), total cholesterol ( < 0.001), triglycerides (=0.042), and alanine aminotransferase (=0.027) when compared with the baseline. One-year of recombinant human growth hormone treatment could improve cardiometabolic risk markers, without adverse effects on glucose homeostasis in boys with obesity.
人们已经认识到，肥胖者更有可能生长激素分泌不足。最近的研究也证实，生长激素/胰岛素样生长因子 1 轴的异常与肥胖者的心血管并发症有关。然而，人们对于重组人生长激素治疗是否能改善肥胖儿童的心血管和代谢风险知之甚少。本研究旨在评估一年生长激素治疗对肥胖相关并发症的影响，并评估其在肥胖中国男孩中的安全性。
18 名肥胖男孩接受了为期一年的重组人生长激素治疗。所有肥胖男孩在基线时均进行了人体测量学测量、内分泌检测和心血管风险标志物检测，并在 3 个月、6 个月、9 个月和 12 个月时进行了随访。
重组人生长激素治疗一年后，体重指数标准差评分降低（<0.001），胰岛素样生长因子 1 水平升高（<0.001）。与基线相比，GH 治疗还降低了低密度脂蛋白胆固醇（<0.001）、总胆固醇（<0.001）、甘油三酯（=0.042）和丙氨酸氨基转移酶（=0.027）。
一年的重组人生长激素治疗可以改善心血管代谢风险标志物，而不会对肥胖男孩的血糖稳态产生不良影响。
